Investing.com - Nabriva Therapeutics reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Nabriva Therapeutics announced earnings per share of $-0.18 on revenue of $9.19M. Analysts polled by Investing.com anticipated EPS of $-0.2 on revenue of $8.53M.
Nabriva Therapeutics shares are down 67.11% from the beginning of the year and are trading at $0.2000 , down-from-52-week-high.They are under-performing the Nasdaq which is down 19.03% from the start of the year.
Nabriva Therapeutics shares gained 1.52% in after-hours trade the report.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by UnitedHealth on Friday, July 15, 2022, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on Tuesday, July 19, 2022 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar